Cabozantinib in progressive medullary thyroid cancer.

By R. Elisei, M. Schlumberger, S. Müller, P. Schöffski, M. Brose, M. Shah, L. Licitra, B. Jarzab, V. Medvedev, M. Kreissl and 9 more. Journal of Clinical Oncology, 2013

1,077 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Hepatology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f3215e3d8a74faf4555d5b6c4447c789a8de5df3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Sebastiano Filetti
2. D. Hartl
3. S. Leboulleux
4. L. Locati
5. K. Newbold
6. Mauro Papotti
7. C. Durante
8. A. Berruti

Citations in the corpus

• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, methodology): “approval for these cases was based on their documented ability to improve PFS [158, 159].”